glp 1 insulin secretion glp-1_analogs [TUSOM Schematic pathway showing release of

Addressing these challenges will require not only continued research and policy advocacy, but also culturally sensitive communication strategies to promote understanding, acceptance, and equitable access to GLP-1based treatments

Not all GLP-1 formulations carry the same safety profile during breastfeeding

A licensed provider can help monitor: side effects dose escalation treatment response medication tolerance overall treatment goals Patients should avoid purchasing medications from unsafe or unverified online sources

Starting July 1, 2026, eligible patients may have a new pathway to access GLP-1 medications for weight management through the Medicare GLP-1 Bridge Program